Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
AssigneeCel-Sci Corporation
InventorsDaniel H. Zimmerman, Donald A. Elliott
Life of this patent
Estimating the term…
Abstract
The present invention relates to a heterofunctional cellular immunological reagent comprising at least two T cell specific binding ligands covalently linked together, wherein one of the T cell specific binding ligands binds to a specific class or subclass of T cells and another of the T cell specific binding ligands is an antigen associated with disease or a causative agent of disease, or epitope thereof. The present invention also relates to vaccines containing the heterofunctional cellular immunological reagents and methods for the use of the same.
Claims18
An immunomodulatory composition effective for the prevention or treatment of disease comprising:
- (A) a pharmaceutically effective amount of an immunomodulatory compound comprising
- at least a first peptide for modulating T cell activity which is a Portion of a polypeptide molecule selected from the group consisting of a non-polymorphic region of MHC Class I, a non-polymorphic region of MHC Class II, lymphocyte function associated molecule-3, antibodies to CD-2, antibodies to CD-3, antibodies to CD-4, antibodies to CD-8, lectins, lymphoklines, and portion of the Fc region of the heavy chain of immunoglobulins,
- and at least a second peptide which is an antigenic peptide associated with disease or a causative agent of disease,
- each of the first and second peptides being a portion of a different polypeptide and each comprising up to about 35% of the total number of amino acids of the polypeptide, and being covalently linked together, and,
- (B) a pharmaceutically acceptable carrier or diluent.
A method of prevention of a disease comprising administering to a disease susceptible subject,
- a therapeutically effective amount of an immunomodulatory compound comprising at least a first peptide for modulating T cell activity which is a portion of a polypeptide molecule selected from the group consisting of a non-polymorphic region of MHC Class I, a non-polymorphic region of MHC Class II, lymphocyte function associated molecule-3, antibodies to CD-2, antibodies to CD-3, antibodies to CD-4, antibodies to CD-8, lectins, lymphokines, and portion of the Fc region of the heavy chain of immunoglobulins,
- and at least a second peptide which is an antigenic pepotide associated with disease or a causative agent of disease,
- each of the first and second peptides being a portion of a different polyoeptide and each comprising up to about 35% of the total number of amino acids of the polypeptide, and being covalently linked together.
A method of treatment of a disease in a patient afflicted with the disease, comprising administering to the patient, a
- (A) a therapeutically effective amount of an iminunomudulator compound comprising an immunomodulatory compound comprising at least a first peptide for modulating T cell activity which is a portion of a polypeptide molecule selected from the group consisting of a non-polymorphic region of MHC Class I, a non-polymorphic region of MHC Class II, lymphocyte function associated molecule-3, antibodies to CD-2, antibodies to CD-3, antibodies to CD-4, antibodies to CD-8, lectins, lymphokines, and portion of the Fc region of the heavy chain of immunoglobulins,
- and at least a second peptide which is an antigenic peptide associated with disease or a causative agent of disease,
- each of the first and second peptides being a portion of a different polypeptide and each comprising up to about 35% of the total number of amino acids of the polypeptide, and being covalently linked together.
Dependencies are inferred from the claim text.